-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 14, Johnson & Johnson Innovative Pharmaceuticals announced that its two innovative treatment plans were successfully included in the 2026 national medical insurance catalogue. Among them, Anliwei was included for the first time, and Megakesu added an additional indication, covering major diseases such as systemic myasthenia gravis and multiple myeloma.
Share
Listen to the news
On November 14, Johnson & Johnson Innovative Pharmaceuticals announced that its two innovative treatment plans were successfully included in the 2026 national medical insurance catalogue. Among them, Anliwei was included for the first time, and Megakesu added an additional indication, covering major diseases such as systemic myasthenia gravis and multiple myeloma.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending